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Amelioration of Autoimmune Arthritis in Mice Treated With 
the DNA Methyltransferase Inhibitor 5′- Azacytidine
Dániel M. Tóth,1 Timea Ocskó,1 Attila Balog,2 Adrienn Markovics,1 Katalin Mikecz,1 László Kovács,2 
Meenakshi Jolly,1 Aleksandra A. Bukiej,1 Andrew D. Ruthberg,1 András Vida,1 Joel A. Block,1 Tibor T. Glant,1 and 
Tibor A. Rauch3
Objective. Disease- associated, differentially hypermethylated regions have been reported in rheumatoid arthritis 
(RA), but no DNA methyltransferase inhibitors have been evaluated in either RA or any animal models of RA. The 
present study was conducted to evaluate the therapeutic potential of 5′- azacytidine (5′- azaC), a DNA methyltrans-
ferase inhibitor, and explore the cellular and gene regulatory networks involved in the context of autoimmune arthritis.
Methods. A disease- associated genome- wide DNA methylation profile was explored by methylated CpG island 
recovery assay–chromatin immunoprecipitation (ChIP) in arthritic B cells. Mice with proteoglycan- induced arthritis 
(PGIA) were treated with 5′- azaC. The effect of 5′- azaC on the pathogenesis of PGIA was explored by measuring 
serum IgM and IgG1 antibody levels using enzyme- linked immunosorbent assay, investigating the efficiency of class- 
switch recombination (CSR) and Aicda gene expression using real- time quantitative polymerase chain reaction, mon-
itoring germinal center (GC) formation by immunohistochemistry, and determining alterations in B cell subpopulations 
by flow cytometry. The 5′- azaC– induced regulation of the Aicda gene was explored using RNA interference, ChIP, 
and luciferase assays.
Results. We explored arthritis- associated hypermethylated regions in mouse B cells and demonstrated that DNA 
demethylation had a beneficial effect on autoimmune arthritis. The 5′- azaC–mediated demethylation of the epigenet-
ically inactivated Ahr gene resulted in suppressed expression of the Aicda gene, reduced CSR, and compromised 
GC formation. Ultimately, this process led to diminished IgG1 antibody production and amelioration of autoimmune 
arthritis in mice.
Conclusion. DNA hypermethylation plays a leading role in the pathogenesis of autoimmune arthritis and its 
 targeted inhibition has therapeutic potential in arthritis management.
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic inflammatory autoim-
mune disorder that primarily leads to joint destruction. B cells play 
an indispensable role in its initiation via the production of high- 
affinity autoantibodies. It has recently been suggested that dys-
regulation of the B cell epigenome can contribute to this antibody 
production (1).
Currently, there is no cure for RA, but treatments can pro-
vide alleviation of symptoms and modify disease progression. In 
most cases, the optimal treatment can only be achieved through 
a combination of different drugs (2). When a combination of 
traditional disease- modifying antirheumatic drugs, nonsteroidal 
antiinflammatory drugs, and/or low- dose glucocorticoids does 
not provide a satisfactory response, highly specific biologic 
agents are introduced into the treatment regimen (2,3). Highly 
effective epigenetic enzyme inhibitors have already been devel-
oped, and their therapeutic potential has been demonstrated 
in cancer (4). However, no such drug is currently used to treat 
RA (5). Epigenetic enzyme targeting drugs represent a novel 
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approach that might replace or be used in combination with 
conventional arthritis therapies to achieve more effective arthritis 
management.
DNA methylation, one of the most common epigenetic 
modifications, is catalyzed by DNA methyltransferases and 
associated with gene silencing when it takes place in promoter 
regions (6). Recent studies have shown that RA pathogenesis 
is associated with DNA methylome changes similarly to car-
cinogenesis. In both diseases characteristic global DNA hypo-
methylation (decreased methylation) events affecting intergenic 
and intragenic regions (7–9) and de novo hypermethylated 
(increased methylation) promoters have been described (8,10). 
Induced demethylation of disease- specific hypermethylated 
promoters using DNA methyltransferase inhibitors, such as 
5′- azacytidine (5′- azaC), can rescue the epigenetically inacti-
vated genes, resulting in impaired disease progression (11,12). 
However, the significance of DNA hypermethylation in RA 
pathogenesis has been shown only indirectly (13). We hypoth-
esized that locus- specific hypermethylation in B cells may play 
a role in arthritis pathogenesis and that DNA methylation inhib-
itors may have therapeutic potential in RA.
Herein, we report that low- dose 5′- azaC treatment has a 
notable effect on disease progression in proteoglycan- induced 
arthritis (PGIA), a murine model of RA (14). The 5′- azaC–medi-
ated suppressive effect is due to transcriptional silencing of 
activation- induced cytidine deaminase (AID), an enzyme respon-
sible for multiple catalytic steps of high- affinity antibody matu-
ration encompassing class- switch recombination (CSR) and 
somatic hypermutation (15,16). Furthermore, AID plays a pivotal 
role in germinal center (GC) formation (17), the site of autoanti-
body production in secondary lymphoid organs (18). We demon-
strate that aryl hydrocarbon receptor (AHR) transcription factor, 
which is known to be involved in B cell differentiation (19) and 
directly regulates Aicda expression (20), is rescued from arthritis- 
associated promoter hypermethylation in B cells after 5′- azaC 
treatment and contributes to the suppression of antibody pro-
duction. These data  promote consideration of epigenetic drugs 
in arthritis therapy.
MATERIALS AND METHODS
Methylated CpG island recovery assay (MIRA). MIRA–
chromatin immunoprecipitation (ChIP) was performed as previously 
described. MIRA- enriched DNA fractions were analyzed by quanti-
tative polymerase chain reaction (qPCR) wherein the Xist promoter 
and mouse Gapdh or human TBP promoters were used as positive 
and negative controls, respectively (Supplementary Table 1, available 
on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.40877/ abstract). Measured Ct values were 
compared to negative control promoter–related Ct values as 1- fold 
baseline methylation level. DNA methylation raw data files are acces-
sible at NCBI GEO (accession no. GSE98939).
Gene expression analysis using Agilent microar-
ray platforms. RNA sample labeling, array hybridization, and 
primary data analysis were performed by Arraystar. Microarray 
data are available from the NCBI GEO database (accession no. 
GSE98932).
Induction and assessment of PGIA in mice and 5′- 
azaC treatment. To induce PGIA, 3- month old female wild- type 
BALB/c mice (Charles River) were immunized intraperitoneally 
with human PG as previously described (14). At disease onset, 
the degree of arthritis in each paw was visually scored for redness 
and swelling on a scale of 0–4 every other day (21). The scoring 
was performed by one individual (TTG) in a blinded manner. Mice 
with a score of ≥1 on at least 1 limb were divided into 2 groups. 
The 5′- azaC–treated mice with PGIA received 2 mg/kg of 5′- azaC 
(Sigma- Aldrich) IP every other day for either 2 weeks or 4 weeks. 
The 5′- azaC was freshly dissolved at 0.5 mg/ml concentration in 
saline solution. The control mice with PGIA received saline solu-
tion alone. For in vitro tests, samples were obtained from the 
mice treated for 2 weeks. The animal studies were reviewed and 
approved by the Institutional Animal Care and Use Committee 
(IACUC) of Rush University Medical Center (IACUC # 15–065).
Histologic analysis. Tissue sections from mouse hind 
limbs were prepared, processed, examined, and photographed 
as previously described (21).
Enzyme- linked immunosorbent assay (ELISA). 
Briefly, IgM isotype control (catalog no. 02- 6800; ThermoFisher) 
or mouse purified IgG1 (0.025 μg/well) was coated onto an 
ELISA plate. IgM horseradish peroxidase (HRP) antibody (cata-
log no. 04- 6820; ThermoFisher) was diluted to 1:2,000 in phos-
phate buffered saline (PBS) and added to serum samples diluted 
1:100. IgG1 HRP antibody (catalog no. 559626; BD Biosciences) 
was diluted to 1:40,000 and added to serum samples diluted 
1:160,000. For no- serum control (NSC), diluted antibodies were 
incubated in PBS. After a 1- hour incubation at room temper-
ature, samples were added to coated wells and incubated for 
an additional hour at room temperature. After washes, the color 
reaction was developed and the optical density (OD) was read 
using a Synergy 2 ELISA reader. The OD of the NSC well was 
set to 100% binding, and the percentage of inhibition was cal-
culated according to the formula % inhibition = 100−[(ODsample 
× 100)/ODNSC]. To measure serum levels of the cytokine inter-
leukin- 4 (IL- 4), a mouse IL- 4 ELISA kit (catalog no. 555232; BD 
Biosciences) was used according to the recommendations of 
the manufacturer.
Isolation of B cells and human peripheral blood 
mononuclear cells (PBMCs). Mouse spleen cells were iso-
lated, and an immunomagnetic selection kit (StemCell) was used 
for negative B cell selection, according to the recommendations 
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of the manufacturer. Peripheral blood samples were obtained 
from consenting treatment- naive RA patients and from consent-
ing healthy individuals (Supplementary Table 2, available on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40877/ abstract) at Albert Szent- Györgyi Clinical 
Center and Rush University Medical Center under Ethics Com-
mittee– and IRB- approved protocols (Hungarian ETT TUKEB905/
PI/09 and RUMC 13082202- IRB01). PBMCs were separated on 
a Ficoll density gradient within 1 hour of blood draw, and were 
then stored in RNAlater solution (ThermoFisher) until RNA and 
DNA preparation. Human B cells were isolated from peripheral 
blood using a negative immunomagnetic selection kit (StemCell) 
according to the recommendations of the manufacturer.
RNA isolation, complementary DNA (cDNA) syn-
thesis, and real- time qPCR. Total RNA preparation, cDNA 
synthesis, and real- time qPCR were conducted as previously 
described (17). Measured Ct values were normalized to Hprt1 
(mouse samples) or β- actin (human samples). Relative expres-
sion was calculated using CFX Manager software (Bio- Rad). The 
primers used are listed in Supplementary Table 1, available on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40877/ abstract.
Digestion- circulation qPCR. Digestion- circulation qPCR 
was performed based on the method described by Lumsden et al 
(22) with modifications. Quantitative PCR was used to quantify 
circulated DNA products. The qPCR was performed in 25 μl final 
volume using 5 μl circulated DNA, SsoAdvanced Universal SYBR 
Green Supermix (Bio- Rad), and primers (Supplementary Table 1) 
at 0.5 μM final concentration. The qPCR conditions were as fol-
lows: 94°C for 2 minutes, 40 cycles at 94°C for 8 seconds, and 
62°C for 30 seconds. Circulated nicotinic acetylcholine receptor 
(nAChR) DNA was used for normalization. Relative quantities of 
IgG1- specific recombinant DNA (Sμ−Sγ1) were calculated by 2−ΔCt 
equation, where ΔCt = CtSμ−Sγ1−CtnAChR.
Flow cytometric analysis. Erythrocytes were lysed 
from mouse spleen and bone marrow (BM) cells by hypotonic 
buffer, then Fc receptors (FcR) were blocked with TruStain 
FcX anti- mouse CD16/CD32 (catalog no. 101320; BioLegend) 
and surface antigens were stained with fluorescence- labeled 
antibodies (Supplementary Table 3, available on the Arthritis 
& Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40877/ abstract). Data acquisition and analy-
sis were performed using a FACSCanto II instrument and BD 
FACSDiva software (version 5.0).
Immunohistochemistry. Mouse spleens and lymph 
nodes were embedded and snap- frozen in Tissue- Tek OCT 
compound (Sakura Finetek), cut on a Microm HM 550 cryo-
stat (Microm International), and stored at −20°C until used. 
Sections were fixed by cold 100% acetone (Sigma- Aldrich) 
and blocked with 1% normal goat serum (ThermoFisher) in 
PBS, then immunostained with fluorescence- labeled antibod-
ies (Supplementary Table 3) for 1 hour. Stained sections were 
post- fixed in 10% formalin and images were captured on a 
Zeiss LSM 700 confocal microscope and analyzed with Zen 
2.0 software (Zeiss).
Cell cultures and in vitro 5′- azaC treatment. A20 
BALB/c mouse B lymphoma and HEK 293T cell lines were 
purchased from ATCC and were maintained in Dulbecco’s 
modified Eagle’s medium (Sigma- Aldrich) supplemented with 
10% fetal bovine serum (FBS; HyClone) and antibiotics. The 
human B cell line GM12878 was purchased from the Coriell 
Institute of Aging Cell Repository and was cultured in RPMI 
1640 medium (Lonza) supplemented with 15% FBS and anti-
biotics. All cells were maintained under standard culture con-
ditions.
The 5′- azaC was dissolved in DMSO at a 10 mM concen-
tration and stored at −20°C until used. A20 cells were plated into 
6- well plates (2 × 105 cell/ml) in medium supplemented with 5′- 
azaC at a 10 μM final concentration. Control samples were treated 
with DMSO at a 0.1% final concentration. Cell cultures were incu-
bated for 24, 48, or 72 hours. Media with the same reagents were 
replaced with fresh media every 24 hours.
Western blot analyses. A20 cells were treated with 5′- 
azaC for 48 hours, and then nuclear and cytoplasmic extracts 
were prepared using a Nuclei EZ Prep kit (Sigma- Aldrich) accord-
ing to the manufacturer’s instructions. Protein concentrations 
were determined using a BCA Protein Assay kit (ThermoFisher) 
and a Synergy 2 ELISA reader (BioTek Instruments). Protein 
extracts were separated on 4–20% sodium dodecyl sulfate–poly-
acrylamide gels (Bio- Rad), blotted onto Immuno- Blot membranes 
(Bio- Rad), then blocked with Tris buffered saline–0.05% Tween 
20 containing 3% nonfat milk, and incubated with the following 
primary antibodies at 4°C overnight: anti- Ahr (1:500) (catalog no. 
GTX22769; GeneTex), anti- Aicda (1:625) (catalog no. ZA001; 
ThermoFisher), antilamin β (1:300) (catalog no. sc6217; Santa 
Cruz Biotechnology), and anti- GAPDH (1:10,000) (catalog no. 
G9545; Sigma- Aldrich). HRP- conjugated secondary antibod-
ies were purchased from Santa Cruz Biotechnology. Pierce ECL 
Western Blotting Substrate (ThermoFisher) was used to generate 
a chemiluminescent signal, which was detected by radiography 
and developed in an Alphatek AX200 machine.
RNA interference study. An Ahr- specific short hairpin 
RNA (shRNA) sequence (Supplementary Table 1) was inserted into 
the pU6Abase vector (23) downstream of the human U6 promoter 
(pU6AshRNA). Exponentially growing A20 cells (107) were sus-
pended in electroporation buffer (20 mM HEPES, 135 mM KCl, 2 
mM MgCl2, and 0.5% Ficoll 400, pH 7.6) together with 20 μg plas-
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mid DNA. Electroporation was carried out using 940 volts/cm and 
950 μF in a Gene Pulser II machine (Bio- Rad). Cells were plated 
onto 6- well plates and after a 12- hour incubation they were treated 
with 10 μM 5′- azaC. Twenty- four hours later the cells were resus-
pended in fresh tissue culture medium supplemented with 10 μM 
5′- azaC and incubated for an additional 24 hours before isolation 
of total RNA. The pU6Abase without insert was used as control.
ChIP assay. ChIP assay was performed on A20 cells after 
treatment with 10 μM 5′- azaC for 48 hours. For IP, 50 μg pre-
cleared chromatin was incubated with 20 μg rabbit polyclonal 
anti- Ahr antibody (catalog no. sc5579; Santa Cruz Biotechnol-
ogy) or incubated without antibody (mock). DNA–Ahr antibody 
complexes were collected using magnetic beads. DNA–AHR anti-
body complexes were eluted and reverse crosslinked as input. 
One microliter of the eluted DNA fraction was used for qPCR in 
which region- specific primers were used (Supplementary Table 
4, available on the Arthritis & Rheumatology web site at http://
onlin elibr ary.wiley.com/doi/10.1002/art.40877/ abstract). Quanti-
tative data were calculated by the ΔΔCt method and presented 
as fold enrichment compared to the values for the mock- treated 
samples.
Figure 1. Amelioration of autoimmune arthritis in mice treated with 5′- azacytidine (5′- azaC). A, Heatmap of differentially methylated regions 
(left) and arthritis- associated gene expression changes (right) in B cells from naive mice (n = 3) and mice with proteoglycan- induced arthritis 
(PGIA; n = 3). Pie charts depict the methylation pattern (left) and gene expression pattern (right) of the annotated sites and genes in samples 
from mice with PGIA. B and C, Arthritis scores for mice with PGIA treated with vehicle (saline) (n = 19 in B and 24 in C) and mice with PGIA 
treated with 5′- azaC (n = 21 in B and 28 in C) intraperitoneally every other day for 2 weeks (B) or 4 weeks (C). Values are the mean ± SEM. 
* = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001 versus vehicle, by two- way analysis of variance (ANOVA) with Sidak’s test. D, 
Body weight of mice injected with dimethyldioctadecylammonium bromide (DDA) adjuvant and treated with vehicle (n = 10), mice injected with 
DDA adjuvant and treated with 5′- azaC (n = 10), mice with PGIA treated with vehicle (n = 24), and mice with PGIA treated with 5′- azaC (n = 
28). Values are the mean ± SEM. # = P ≤ 0.05; ## = P ≤ 0.01, mice injected with DDA treated with vehicle versus mice with PGIA treated with 
vehicle; * = P ≤ 0.05; *** = P ≤ 0.001, mice injected with DDA treated with 5′- azaC versus mice with PGIA treated with 5′- azaC, by two- way 
ANOVA with Sidak’s test. E, Representative images of histopathologic features of hematoxylin and eosin–stained ankle joints from mice injected 
with DDA adjuvant, mice with PGIA treated with vehicle, and mice with PGIA treated with 5′- azaC. Arrows indicate bone- eroding inflammatory 
tissue. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40877/abstract.
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Luciferase assay. Briefly, the mouse Aicda minimal 
promoter and the longer variant (including region 13, named 
pGL4.1- Aicda- p+13r) or the shorter variant (without region 13, 
named pGL4.1- Aicda- p+Δ13r) of the intronic region of Aicda 
was cloned into pGL4.1 (Promega). A reporter plasmid with a 
human AHR- overexpressing plasmid (pCMV- hAHR; OriGene) 
or with a control vector (pCMV- EGFP; Addgene) were cotrans-
fected into HEK 293T cells. Twenty- four hours after transfection, 
luciferase activity was measured. The relative luciferase activity 
was calculated by normalization of measured relative lumines-
cence units to protein concentrations.
Statistical analysis. All statistical analyses were performed 
using GraphPad Prism software, version 7.04. Results are reported 
as the mean ± SEM. If the significance level for the pretest for nor-
mality (Shapiro- Wilk) was less than 0.05, the Mann- Whitney U test 
was used. If the significance level for the pretest was greater than 
0.05, Student’s unpaired 2- tailed t- test was used. Comparisons of 
more than 2 groups were performed by one- way analysis of vari-
ance (ANOVA), and groups affected by 2 factors were compared 
by two- way ANOVA followed by Sidak’s post hoc comparison. 
P values less than 0.05 were considered significant.
RESULTS
Elimination of PGIA symptoms in mice treated with 
low doses of a DNA hypomethylating agent. To investigate 
the role of DNA methylation in RA pathology, we conducted an 
integrative analysis by exploring genome- wide DNA methylation 
and accompanying gene expression changes in B cells from mice 
with PGIA (Figure 1A). We observed dominant arthritis- associated 
hypomethylation and rare hypermethylation events in the investi-
gated intergenic and intragenic regions in arthritic B cells (Supple-
mentary Table 5, available on the Arthritis & Rheumatology web site 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.40877/ abstract). 
However, DNA methylation profile changes were infrequently fol-
lowed by gene expression changes, implying that most of the 
methylation events have no direct effects on gene expression.
We recognized that carcinogenesis- and arthritis- associated 
DNA methylation profile changes are similar in a sense, as both 
are characterized by dominant genome- wide hypomethyla-
tion affecting intergenic and intragenic regions, and infrequent 
promoter- specific hypermethylation events (24). Accordingly, 
we hypothesized that a demethylating agent that proved to be 
effective in cancer treatment could also be effective in arthritis 
 therapy. We treated arthritic mice with low- dose 5′- azaC every 
other day for 2 weeks, which resulted in gradual reduction of dis-
ease severity and halted arthritis progression (Figure 1B). Next, 
we started 5′- azaC treatment at a more advanced stage of arthri-
tis and continued treatment for 4 weeks, which similarly reduced 
paw swelling (Figure  1C). Moreover, neither mortality nor toxic 
effect was observed among these mice. This was confirmed by 
the increased body weight of 5′- azaC–treated arthritic mice at the 
fourteenth administration of 5′- azaC (Figure  1D). Furthermore, 
arthritis- specific massive joint inflammation, synovial pannus for-
mation, cartilage damage, and bone destruction were undetect-
able by histopathologic analysis in 5′- azaC–treated animals by the 
end of the study (Figure 1E). These results confirmed our working 
hypothesis that 5′- azaC–induced DNA demethylation can be an 
effective approach for the management of autoimmune arthritis.
Attenuated IgG1 antibody production in 5′- azaC–
treated mice with PGIA. The lack of joint inflammation 
prompted us to measure serum levels of IgM and IgG1 antibod-
Figure 2. Attenuation of IgG1 production in mice with PGIA treated with 5′- azaC. A and B, Changes in IgM (A) and IgG1 (B) antibody levels 
in mice with PGIA treated with vehicle (n = 8) and mice with PGIA treated with 5′- azaC (n = 8). Sera were collected before the first and after the 
last 5′- azaC treatment. Values are the percent of pretreatment level. C, Relative quantity of IgG1- specific class- switched recombinant genomic 
DNA (Sμ−Sγ1) in mice with PGIA treated with vehicle (n = 5) and mice with PGIA treated with 5′- azaC (n = 5). D and E, Relative (rel) normalized 
(norm) expression of mRNA for germline (Iμ−Cμ and Iγ1–Cγ1) and post- recombination (Iμ−Cγ1) IgG1 (D) and for Aicda (E) in B cells from mice 
with PGIA treated with vehicle (n = 8) and mice with PGIA treated with 5′- azaC (n = 8). Bars show the mean ± SEM. * = P ≤ 0.05; ** = P ≤ 0.01, 
by the Mann- Whitney U test in B and by t- test in C–E. See Figure 1 for definitions.
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ies. Samples were collected before the first 5′- azaC treatment and 
when the experiment was terminated. IgM levels were enhanced in 
both animal groups, but IgG1 levels were increased only in vehicle- 
treated mice (Figures 2A and B). This suggested a compromised 
CSR (25,26) in 5′- azaC–treated mice. Hence, we measured IgG1- 
specific genome rearrangement in B cells using a modified version 
of digestion- circulation PCR (22). The level of class- switched DNA 
(Figure 2C) and the level of post- recombination IgG1 messenger 
RNA (mRNA) (Figure 2D) were significantly lower in 5′- azaC–treated 
mice. Since Aicda regulates CSR (26), we determined its expression 
level, which was significantly lower in 5′- azaC–treated animals (Fig-
ure 2E). These data suggest that 5′- azaC inhibits Aicda expression, 
leading to diminished CSR and attenuated antibody production in 
B cells, ultimately resulting in the suppression of arthritis symptoms.
Figure 3. Treatment with 5′- azaC impairs germinal center (GC) formation and shifts former B cell subpopulations in mice with PGIA. A and 
B, GCs in the joint draining lymph nodes (A) and spleens (B) of mice injected with DDA adjuvant, mice with PGIA treated with vehicle, and mice 
with PGIA treated with 5′- azaC. Red shows follicular B cells (phycoerythrin- conjugated B220/CD45R), green shows GL- 7+ B cells (Alexa Fluor 
488–conjugated GL- 7), and blue shows T cells (biotin- conjugated CD4, biotin- conjugated CD8a, and eFluor 450–conjugated streptavidin). 
Arrows indicate GCs in B cell follicles. Original magnification × 100. C and D, Percentage of GC B cells, determined by flow cytometry, within B 
lymphocytes in the lymph nodes (C) and spleen (D) of mice with PGIA treated with vehicle (n = 8) and mice with PGIA treated with 5′- azaC (n = 
8). E, Percentage of plasma cells, determined by flow cytometry, within bone marrow cells from mice with PGIA treated with vehicle (n = 5) and 
mice with PGIA treated with 5′- azaC (n = 5). F–H, Percentage of early prepro–B cells, early pro–B cells, early pre–B cells, and late precursor 
B cells (F), immature and mature recirculating B cells (G), and transitional type 1 (T1), T2, marginal zone (MZ), and follicular (Fo) B cells (H), 
determined by flow cytometry, within B lymphocytes in the bone marrow (F and G) or spleen (H) of mice with PGIA treated with vehicle (n = 11) 
and mice with PGIA treated with 5′- azaC (n = 12). Bars show the mean ± SEM. * = P ≤ 0.05; ** = P ≤ 0.01, *** = P ≤ 0.001; **** = P ≤ 0.0001, 
by the Mann- Whitney U test in C and E and by t- test in D and F–H. See Figure 1 for other definitions.
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Treatment with 5′- azaC inhibits GC formation and 
shifts the proportion of former B cell subpopulations in 
mice with PGIA. Self- reactive antibodies are mainly generated in 
GCs of secondary lymphoid organs (18). Thus, we investigated GC 
formation and determined the proportion of GC B cells in the mouse 
lymph nodes and spleen. Reduced GC formation and significantly 
decreased GC B cell frequency were observed in both organs in 5′- 
azaC–treated mice (Figures 3A–D and Supplementary Figures 1A 
and B, available on the Arthritis & Rheumatology web site at http://
onlin elibr ary.wiley.com/doi/10.1002/art.40877/ abstract). Moreover, 
as a consequence of diminished GC formation, the proportion of 
plasma cells was also decreased in the BM of 5′- azaC–treated ani-
mals (Figure 3E and Supplementary Figure 1C).
To explore the origin of the altered frequency of GC B cells, 
we examined B cell subpopulations in mouse BM and spleen. In 
both organs, the proportions of B cells were significantly lower 
in the lymphocyte compartments in 5′- azaC–treated animals 
(Supplementary Figure 2, available on the Arthritis & Rheuma-
tology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.40877/ abstract). The proportions of early precursor B cells 
were increased (Figure 3F), while the frequencies of late precursor 
(Figure 3F) and immature B cells (Figure 3G) were reduced upon 
5′- azaC treatment. In the periphery, we detected a decreased 
proportion of transitional type 1 (T1) B cells, while the frequen-
cies of follicle- colonizing T2 and marginal zone (MZ) B cells were 
elevated within the B cell populations of 5′- azaC–treated mice 
(Figure 3H). Finally, 5′- azaC treatment also elevated the percent-
age of the mature recirculating B cells in the BM (Figure 3G). The 
proportion of follicular B cells, which are essential in GC responses 
(18), was similar in the vehicle- treated and 5′- azaC–treated mice 
Figure 4. Hypermethylated Ahr regulatory regions in mice with PGIA and treatment- naive patients with rheumatoid arthritis (RA). A, Venn 
diagram of PGIA- associated (up- regulated and down- regulated), marginal zone (MZ)–specific, and germinal center (GC)–specific B cell genes. 
* = includes the Ahr gene. B, Relative (rel) normalized (norm) Ahr mRNA expression in splenic B cells from naive mice (n = 3), splenic B cells from 
mice with PGIA (n = 3), and in the mouse A20 B lymphoma cell line. C, Relative DNA methylation level of the Ahr promoter in splenic B cells from 
naive mice (n = 3) and mice with PGIA (n = 3). D and E, Relative normalized AHR mRNA expression in human peripheral blood mononuclear 
cells (PBMCs) isolated from healthy individuals (n = 19) and treatment- naive RA patients (n = 46) (D) and in human B cells isolated from healthy 
individuals (n = 5) and treatment- naive RA patients (n = 10) (E). F, Relative DNA methylation level of differentially methylated region C of AHR 
in PBMCs from healthy individuals (n = 10) and treatment- naive RA patients (n = 11). In B, C, and F, bars show the mean ± SEM. In D and E, 
symbols represent individual patients; horizontal lines show the mean. * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001, by one- way ANOVA with 
Sidak’s test in B, by t- test in C, and by the Mann- Whitney U test in D–F. See Figure 1 for other definitions.
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with PGIA (Figure 3H and Supplementary Figure 3, available on 
the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.40877/ abstract).
Since follicular B cells can evolve GCs in a T cell–dependent 
manner (27), we investigated the frequency of CD4+ T cells and 
measured serum levels of IL- 4 cytokine, which is predominantly 
produced by GC- forming follicular T helper cells (28). Interest-
ingly, neither the frequency of CD4+ T cells nor the serum level of 
IL- 4 was changed in 5′- azaC–treated mice compared to vehicle- 
treated arthritic animals (data not shown).
Hypermethylated Ahr regulatory regions in arthritic 
mouse B cells and human samples. DNA hypomethylation 
induced by 5′- azaC is nonspecific (29), in contrast to the locus- 
specific Aicda- mediated hypomethylation events in the B cell epige-
nome, which are essential for effective GC formation (17). Accordingly, 
it is conceivable that 5′- azaC–induced demethylation may pro-
voke genes that inhibit GC formation. Taking this into account, our 
aim was to identify genes that could be induced by 5′- azaC and 
suppress Aicda expression. To this end, we compared arthritis- 
associated up- regulated and down- regulated genes (Figure 1A) with 
characteristic sets of MZ and GC B cell genes (30)  (Figure 4A) that 
express Aicda (15,25). We focused on down- regulated genes that 
were also hypermethylated in arthritis, which can be possible tar-
gets of 5′- azaC–triggered activation (Supplementary Table 6, avail-
able on the Arthritis & Rheumatology web site at http://onlin elibr ary.
wiley.com/doi/10.1002/art.40877/ abstract). These down- regulated 
genes included the Ahr gene, which encodes a transcription factor 
that is known to suppress Aicda expression after agonist stimula-
tion (20). Indeed, Ahr expression was down- regulated (Figure 4B) 
and its promoter was hypermethylated in B cells isolated from mice 
with PGIA (Figure 4C and Supplementary Figure 4, available on the 
Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40877/ abstract).
Importantly, the disease specificity of down- regulated AHR 
expression was confirmed in PBMCs and B cells (Figures 4D and 
E) isolated from treatment- naive RA patients. RA- associated DNA 
hypermethylation was not observed in the AHR promoter region; 
however, a distant intergenic region (differentially methylated region 
C) 155 kb upstream of the AHR transcription start site (TSS) was 
differentially  hypermethylated (Figure 4F and Supplementary Figure 
5, available on the Arthritis & Rheumatology web site at http://onlin 
elibr ary.wiley.com/doi/10.1002/art.40877/ abstract). These results 
suggest that the AHR gene can be silenced in a DNA methyla-
tion–dependent manner and that AHR silencing may be involved 
in RA  pathology.
Demethylation of the Ahr promoter plays a signifi-
cant role in the inhibition of Aicda. To verify that 5′- azaC 
induced Ahr expression, we defined the promoter methylation and 
expression of Ahr in B cells. Indeed, Ahr promoter demethylation 
and accompanying elevated Ahr gene expression (Figures 5A and 
B) were identified in 5′- azaC–treated mice with PGIA. To deter-
mine the mechanistic connection between 5′- azaC–induced Ahr 
and Aicda, we conducted experiments with A20 cells, a BALB/c 
mouse B lymphoma cell line (31). In these cells, Ahr expression 
was down- regulated as in arthritic mouse B cells (Figure  4B). 
Furthermore, 5′- azaC treatment evoked a significant increase 
in Ahr expression (Figure 5C) due to its promoter demethylation 
(Figure 5D). Moreover, Ahr was translocated into the nucleus (Fig-
ure 5E), indicating its engagement in transcriptional regulation.
Next, to confirm the involvement of 5′- azaC–induced Ahr in 
down- regulated Aicda expression (Figures  5E and F), we used 
an shRNA- mediated inhibition approach. Treatment with 5′- azaC 
Figure 5. Demethylation induced by 5′- azaC provokes Ahr expression in vivo and in vitro. A, Relative (rel) DNA methylation level of the Ahr 
promoter in B cells from mice with PGIA treated with vehicle (n = 4) and mice with PGIA treated with 5′- azaC (n = 3). B, Relative normalized 
(norm) Ahr mRNA expression in B cells from mice with PGIA treated with vehicle (n = 8) and mice with PGIA treated with 5′- azaC (n = 8). C and 
D, Relative normalized Ahr mRNA expression in A20 cells after 24, 48, and 72 hours of treatment with 10 μM 5′- azaC or 0.1% DMSO as control 
(C) and relative DNA methylation level of the Ahr promoter in A20 cells after 48 hours of treatment with 5′- azaC or control (D) (n = 3 samples 
per group). E, Localization of Ahr and Aicda in the cytoplasm and nucleus of A20 cells treated with 5′- azaC for 48 hours. GAPDH and lamin 
β were used as loading controls. F, Relative normalized Aicda mRNA expression in A20 cells treated with 5′- azaC or control for 48 hours (n = 
3 samples per group). In A–D and F, bars show the mean ± SEM. * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001, by t- test in A, 
B, D, and F and by two- way ANOVA with Sidak’s test in C. See Figure 1 for definitions.
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did not increase Ahr expression when Ahr- specific shRNA was 
expressed in A20 cells, resulting in only a moderate decrease in 
Aicda expression (Figure  6A). Furthermore, we performed Ahr- 
specific ChIP focused on such regions (Supplementary Table 4, 
available on the Arthritis & Rheumatology web site at http://onlin 
elibr ary.wiley.com/doi/10.1002/art.40877/ abstract) in the genomic 
context of the Aicda gene that harbor in silico predicted Ahr bind-
ing sites (32). We detected 5′- azaC–induced Ahr binding in the first 
intron, termed region 13 (Figure 6B). Although region 13 does not 
contain a canonical Ahr binding site (33), it carries reasonably simi-
lar sequences to a ChIP- Seq–defined Ahr binding consensus motif 
(34), which was capable of binding Ahr effectively (Supplementary 
Figure 6, available on the Arthritis & Rheumatology web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.40877/ abstract).
Finally, in transient expression studies, AHR only reduced the 
activity of an Aicda promoter- driven reporter gene if the inserted 
Aicda first intronic segment included region 13 (Figure 6C). These 
data demonstrate that Ahr bound directly to the regulatory region 
of Aicda after 5′- azaC treatment, but this region did not over-
lap with a previously described intronic silencer region (20). Our 
in vitro and in vivo experiments showed that 5′- azaC–induced 
demethylation rescues Ahr from hypermethylation- mediated 
down- regulation. B cell culture–based data demonstrated that 
reactivated Ahr directly contributed to the suppression of Aicda 
expression through a novel regulatory region in B cells. Therefore, 
it is plausible that the Ahr–Aicda regulatory cascade is responsible 
for attenuated GC formation and antibody production, which ulti-
mately ameliorates arthritis symptoms.
DISCUSSION
Targeted inhibition of DNA methylation has already been 
proven to be an effective approach to restoring the expression of 
tumor suppressor genes and their cellular function (12). Herein we 
demonstrated that in vivo treatment with a DNA methyltransferase 
inhibitor has therapeutic potential in autoimmune arthritis as well.
We identified a number of differentially hypermethylated 
regions in arthritic mouse B cells (Figure  1A) and detected 
genome- wide hypomethylation, consistent with the findings of 
previous studies (35). However, the hypomethylation cannot be 
considered disease- specific because DNA demethylation also 
occurs during “normal” B cell maturation and activation (17,36–
38). In contrast, disease- associated, less frequent hypermethyla-
tion events probably play more significant roles in arthritis etiology. 
This concept was supported by the findings of a study investigat-
ing fibroblast- like synoviocytes in RA patients (10) and an in vitro 
study of PBMCs from RA patients (13).
DNA demethylation induced by 5′- azaC halted arthritis pro-
gression in mice (Figures 1B and C), which can be attributed to the 
inhibited production of IgG1 antibodies (Figure 2B), since they can 
participate in joint destruction by forming immune complexes on 
the articular cartilage surface (39). Furthermore, high- affinity anti-
Figure 6. Direct regulation of Aicda by 5′- azaC–induced Ahr. A, Relative (rel) normalized (norm) Ahr and Aicda mRNA expression in A20 
cells transfected with a control plasmid (pUTAbase) alone or transfected with an anti–Ahr short hairpin RNA (shRNA)–expressing plasmid 
(pU6AshRNA) or control plasmid and then treated with 5′- azaC for 48 hours (n = 3 samples per group). B, Chromatin immunoprecipitation 
analysis of Ahr binding to region 13 (Supplementary Table 4, available on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.40877/ abstract) in the first intron of Aicda in A20 cells treated with 5′- azaC or control for 48 hours (n = 3 per group). 
The intergenic region was used as a negative control and the CYP1a1 promoter region was used as a positive control. Data are presented as 
fold enrichment compared to the values for control treatment. C, Relative luciferase activity of the mouse Aicda promoter- driven reporter gene 
alone (pGL4.1- Aicda- p), the Aicda promoter- driven reporter gene with a segment of the first intron of Aicda including region 13 (pGL4.1- Aicda- 
p+13r), or the Aicda promoter- driven reporter gene with the same segment without region 13 (pGL4.1- Aicda- p+Δ13r). Reporter plasmids were 
cotransfected with a human AHR- expressing plasmid (pCMV- hAHR) or enhanced green fluorescent protein (EGFP)–expressing plasmid (pCMV- 
EGFP). Luciferase activity was normalized to cellular protein concentrations (n = 3 samples per group). Bars show the mean ± SEM. * = P ≤ 
0.05; ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001, by two- way ANOVA with Sidak’s test. See Figure 1 for other definitions.
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bodies, including self- reactive antibodies, are generated in GCs of 
secondary lymphoid organs (18) wherein CSR occurs due to high 
Aicda expression (25,26). Thus, the reduced Aicda expression 
and CSR, which ultimately lead to inhibited IgG1 production, can 
be attributed to the diminished GC formation in 5′- azaC–treated 
mice (Figures 3A and B).
To clarify the cause of the decrease in the proportion of GC 
B cells, we determined the frequencies of former B cell subpop-
ulations. The frequencies of these subpopulations were similar to 
those previously found in anti- CD20–depleted mice (40). In light of 
the consistency of the findings, our results and those of the previ-
ous study can be explained in a similar way. The lower proportions 
of total B cells in the lymphocyte compartments after 5′- azaC treat-
ment (Supplementary Figure 2, available on the Arthritis & Rheu-
matology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.40877/ abstract) induced a compensatory mechanism which 
is intended to sustain the constant frequency of follicular B cells 
and resulted in increased proportions of early precursor B cells 
(Figure 3F) (40) or follicular B cell–derived (41) mature recirculating 
B cells (Figure 3G). At the same time, a selective incident with a 
higher negative selection pressure could be induced, resulting in a 
decreased frequency of late precursor, immature (Figures 3F and 
G), and T1 B cells (Figure 3H) (42). Moreover, mature recirculating 
B cells constitute a reservoir for MZ B cells (41); thus, there might 
be a positive relationship between the increased frequencies of 
these cells (Figures 3G and H). Ultimately, these changes did not 
disturb the proportion of GC- forming (18) follicular B cells (Fig-
ure 3H). Taken together with an unchanged frequency of CD4+ T 
cells and serum IL- 4 level, these data suggest that B cell intrinsic 
factors are the cause of diminished GC formation.
The contribution of Ahr to autoimmune arthritis has been 
investigated in two previous studies using the collagen- induced 
arthritis model. In the first study, Ahr altered T cell differentia-
tion and promoted pathogenesis (43), while the other study 
showed that it exerted a preventive effect by inhibiting mesen-
chymal stem cell differentiation (44). Our findings are consist-
ent with those of the latter study and demonstrate that DNA 
hypermethylation–mediated silencing of Ahr contributes to 
arthritis pathogenesis. This hypermethylated region is located 
in the Ahr promoter in arthritic mouse B cells (Figure 4C and 
Supplementary Figure 4, available on the Arthritis & Rheuma-
tology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.40877/ abstract) or in a distant upstream region in RA 
patients (Supplementary Figure 5, available on the Arthritis 
& Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40877/ abstract). ChIP- Seq data demonstrate 
that transcription factors can bind to this distant region (45–
47), suggesting that this region is a B cell–specific enhancer.
We demonstrated that 5′- azaC–induced demethylation 
could rescue Ahr from hypermethylation- related down- regulation 
(Figure 5B). This rescued Ahr contributed to the attenuated IgG1 
production through the suppression of Aicda (Figure 5F), which is 
an essential regulator of GC formation (17). Ahr bound directly to 
the intronic regulatory region of Aicda after 5′- azaC treatment (Fig-
ure 6B), but this region did not overlap with a previously described 
silencer region in the first intron ~1.3 kb downstream from the TSS 
(20). This finding provides evidence of the existence of a differ-
ent Ahr regulatory mechanism in 5′- azaC–treated arthritic B cells, 
which may come from distinct activation methods.
In summary, in this study, we demonstrated that 5′- azaC, a 
Food and Drug Administration–approved anticancer agent used 
for the treatment of various blood cell malignancies, effectively 
treats autoimmune arthritis when administered at low doses 
beginning at the early phase of the disease. Furthermore, we 
explored the notion that the beneficial effect of 5′- azaC is owed 
to compromised GC formation and subsequent reduced antibody 
production in which Ahr promoter demethylation can play a piv-
otal role. Our data provide a foundation for further studies explor-
ing the therapeutic potential of low- dose DNA methyltransferase 
inhibitors in RA and other antibody- dependent diseases.
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